Lazertinib mesylate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2024
- First approval year
- 2024
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Lazertinib mesylate
- Molecular weight
- 668.78
- Structure (SMILES)
- C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1.CS(=O)(=O)O.O
- lazcluze
- Lazcluze
- leclaza
- Leclaza
- jnj 73841937 zcy
- JNJ-73841937-ZCY
- lazcluze
- Lazcluze
- lazertinib mesilate hydrate
- Lazertinib mesilate hydrate
- LAZERTINIB MESILATE HYDRATE [JAN]
- lazertinib mesilate hydrate jan
- lazertinib mesylate
- Lazertinib mesylate
- LAZERTINIB MESYLATE [USAN]
- lazertinib mesylate monohydrate
- Lazertinib mesylate monohydrate
- Lazertinib mesylate monohydrate [MI]
- Lazertinib mesylate monohydrate [WHO-DD]
- lazertinib mesylate monohydrate mi
- lazertinib mesylate monohydrate who dd
- lazertinib mesylate usan
- r 605024
- R-605024
- r605024
- R605024
- yh25448am
- YH25448AM
- ATC classification codes
- L01EB09
Sources for recorded values
- CAS registry numbers
- 2411549-88-5
- ChEMBL ID
- CHEMBL6068478
- InChIKey
- ZJPNGZUERUYZEG-UHFFFAOYSA-N
- PubChem compound IDs
- 163203547
- RxNorm IDs (RxCUI)
- 2691150
- FDA ingredient codes (UNII)
- WUT449BEG5
- Applicant
- JANSSEN BIOTECH
- Approval date
- 19 Aug 2024
- Application number
- NDA219008
- Patents
- 7
- Designations
- 0
- Earliest recorded loss of exclusivity
- 1 Aug 2041
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Drug name stem
- -tinib
Administration routes
- Oral
Mechanisms of action
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
- Action type
- Inhibitor
- Target
- Epidermal growth factor receptor
- Protein identifier
- P00533
Open Targets mechanisms
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
- Action type
- Inhibitor
- Target
- Epidermal growth factor receptor
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0003060
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 4
- Event
- embolism venous
- Reports
- 2
- Reporting signal score
- 8.68753
- Event
- infusion related reaction
- Reports
- 7
- Reporting signal score
- 21.1031
- Event
- paronychia
- Reports
- 3
- Reporting signal score
- 13.3184
- Event
- skin disorder
- Reports
- 4
- Reporting signal score
- 13.9953
- Hydrogen bond acceptors
- 10
- Hydrogen bond donors
- 2
- Polar surface area
- 109.67
- Calculated partition coefficient (ALogP)
- 4.1
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 10
- Heavy atoms
- 47
- Molecular formula
- C31H40N8O7S
- Monoisotopic mass
- 668.27406682
- Natural product
- No
Related records
Trials (40)
- A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
- A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants
- A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
- A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)
- A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants
- A Study of Lazertinib (JNJ-73841937) in Healthy Participants
- A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants
- A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy
- A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
- A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
- A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
- A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
- A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants
- A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)
- Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI
- Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations
- Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
Approved for (1)
In development for (1)
- Neoplasm Phase 1
Targets (1)
- EGFR Epidermal growth factor receptor erbB1 inhibitor